Azenta offers a cash-rich, sticky biostorage platform at a discounted valuation, but upside depends on proving that operational fixes can turn recurring sample infrastructure into durable margin expansion.
Overview
Azenta is a pure-play life sciences tools and services company built around sample lifecycle management and genomic analysis after divesting its semiconductor automation business. Its SMS segment provides automated cold storage, outsourced biorepositories, logistics, and consumables, while Multiomics, led by GENEWIZ, offers sequencing, NGS, gene synthesis, and bioinformatics. The company serves top biopharma, biotech, academic, and healthcare customers, including all top 20 global pharma companies. Its core appeal lies in protecting irreplaceable biological samples through compliant, auditable, temperature-controlled infrastructure with high customer switching costs.